Celon Pharma Hosting a Virtual Capital Markets Day on Wednesday, April 21st

KIELPIN, Poland, April 19, 2021 (GLOBE NEWSWIRE) — Celon Pharma S.A. today announced that it will host a virtual Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET.

The webinar will feature a discussion hosted by Key Opinion Leader Dr. Piotr Wierzbiński and fellow scientists – Prof. Joanna Chorostowska-Wynimko, Instytut Gruzlicy i Chorob, and Prof. Eduard Vieta, University of Barcelona, covering leading pipeline assets such as esketamine in bipolar depression, and other programs in solid tumors and inflammatory disease.

Celon’s management team will also provide a corporate business update with a discussion of important financial metrics.

A Q&A session will follow the formal presentations.

To register for the webinar, please click here.

Piotr Wierzbiński, PhD is a doctor of Medical Sciences, and Medical Doctor and is a graduate with honors of the Faculty of Medicine of the Medical University of Łódź, Poland. From 2006 to 2014 he held the position of assistant in the Clinic of Adult Psychiatry of the Medical University of Łódź, Poland. Currently, Piotr maintains a private medical practice. He is also a member of the Polish Psychiatrists’ Association and a member of International Society for Sports Psychiatry. He is the author of over 70 medical publications including those concerning panels on epidemiology and pharmacotherapy in psychiatry, sports psychiatry, on suicide, and on the overlapping fields of somatic medicine and psychiatry.

Joanna Chorostowska-Wynimko – MD, PhD is a Professor of Medicine, Head of the Department of Genetics and Clinical Immunology and a Consultant in Respiratory Medicine at the National Institute of Tuberculosis and Lung Diseases (NITLD) in Warsaw, Poland. She is the current Secretary General of the European Respiratory Society (2019-2022). Professor Chorostowska-Wynimko received training as a post-doctoral researcher at Department of Physiology and Molecular Biology, Medical College of Ohio (2001–2002), and at the Urology Research Center, Medical University of Toledo (2009). She has also received Board certification in Laboratory Immunodiagnostics (2011), Respiratory Diseases (2001), and Internal Medicine (1997).

Professor Chorostowska-Wynimko is widely published with over 220 articles in peer-reviewed journals, and is a principal investigator and coordinator on many clinical studies and scientific programs. Professor Chorostowska-Wynimko’s clinical interest is mostly devoted to molecular diagnostic of lung cancer (ctDNA, liquid biopsy, novel biomarkers) as well as COPD and alpha-1 antitrypsin deficiency. She is a coordinator of the National Expert Group for Lung Cancer, member of the Medical Steering Committee and leaf of the Cross-Border Care Committee of the European Reference Network-LUNG. coordinator of the Central-Eastern European Alpha-1 Network, coordinator of the National Alpha-1 Antitrypsin Deficiency Registry, and head of the Polish Alpha-1 Antitrypsin Diagnostic Lab.

Eduard Vieta Professor of Psychiatry and Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic, where he also leads the Bipolar and Depressive Disorders Program in Barcelona, Catalonia, Spain. His unit is one of the worldwide leaders in clinical care, teaching and research on affective disorders. Dr. Vieta is also the current Scientific Director of the Spanish Research Network on Mental Health (CIBERSAM). He has received the Aristotle award (2005), the Mogens Schou award (2007), the Strategic Research award of the Spanish Society of Biological Psychiatry (2009), the Official College of Physicians award to Professional Excellence (2011), the Colvin Price on Outstanding Achievement in Mood Disorders Research by the Brain and Behaviour Research Foundation (2012), the Clinical Neuroscience Lilly award by the International College of Neuropsychopharmacology (CINP 2014), the Simon Bolivar Award (American Psychiatric Association 2017) and the Research Price of the World Federation of Societies of Biological Psychiatry (WFSBP, 2017). He has been named twice best psychiatrist in Spain (Monitor sanitario, El Español), honorary member of the Spanish Society of Biological Psychiatry, and Doctor Honoris Causa by the University of Valencia. He has authored more than 950 original articles, 450 book chapters and 45 books. His h index is 134 and has over 66.000 citations (Google Scholar), which makes him the most cited scientist worldwide in the field of bipolar disorder over the last 8 years and one of the world’s most influential scientific minds, according to Clarivate Analytics ranking (Highly Cited). His papers have over 600.000 downloads. Furthermore, he is Editor-in-Chief of European Neuropsychopharmacology and has served as invited professor at McLean Hospital and Harvard University and as neuroscience scientific advisor to the European Presidency.

ABOUT CELON PHARMA

Celon Pharma is an integrated biopharmaceutical company which designs, develops, manufactures and distributes pharmaceutical products. It was founded in 2002 by Maciej Wieczorek, PhD. The Company currently has approx. 450 employees. It employs approx. 160 scientists responsible for research and development, half of whom either have a PhD or are in the process of acquiring their PhD. The Company’s pipeline includes more than a dozen projects for the development of innovative drugs with therapeutic groups such as oncology, neuro-psychiatry, autoimmunity and metabolism. The Company has its own research and development laboratories, which allow it to develop its own pharmaceutical technologies by using extensive laboratory equipment resources, as well as the experience and expertise of its staff. It also has a modern manufacturing facility where dry pharmaceutical forms are manufactured. Over the last few years, the Company has introduced products into the market in the following therapeutic areas: oncology, central nervous system diseases, cardiology, HIV treatment, respiratory diseases. The Company has been developing the technology for manufacturing inhalation drugs and several projects of innovative drugs since 2007. It has been listed on the Warsaw Stock Exchange since 2016. www.celonpharma.com

Disclaimer
This press release (“Press release”) has been prepared by Celon Pharma S.A. (the “Company”). By reading the Press release, you agree to be bound by the following limitations.

This Press release is strictly confidential to the recipient. Neither this Press release or any part hereof nor the information contained herein may be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person or published, in whole or in part.

If you gain access to this Press release by mistake, or you are not an addressee of this Press release or a person authorized to use this Press release, please bear in mind the confidential nature of this Press release and immediately contact the Company in order to return it to the Company.

The Press release does not constitute an offer to sell or subscribe for or a solicitation of an offer to purchase or subscribe for securities. This Press release is provided for informational purposes only. This Press release does not constitute or form part of and should not be construed as an offer, solicitation or invitation to sell or issue, or an offer, solicitation or invitation to, subscribe for, underwrite, buy or otherwise acquire, securities of the Company or any of its subsidiaries in any jurisdiction, or an inducement/recommendation to enter into investment activity in any jurisdiction. Neither this Press release nor any part hereof, nor the fact of its distribution or issuance, shall form the basis of, or be relied on in connection with, any contract, commitment or investment decision whatsoever.

The information contained herein is only preliminary and indicative and does not purport to contain the information that would be required to evaluate the Company, its financial position and/or any investment decision. This Press release is not intended to provide, and should not be relied upon for, accounting, legal or tax advice nor does it constitute an investment recommendation. This Press release is given in conjunction with an oral press release and should not be taken out of context.

No information included in this Press release may be considered as investment advice or investment recommendation. The information contained in the Press release has not been independently verified. No repress release, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein.

Matters discussed in this Press release may constitute forward-looking statements. Forward-looking statements constitute statements that are other than statements of historical fact. Statements which include the words “expects”, “intends”, “plans”, “believes”, “projects”, “anticipates”, “will”, “targets”, “aims”, “may”, “would”, “could”, “continue” and similar statements of a future or forward-looking nature identify such forward-looking statements. Forward-looking statements include in particular statements regarding the financial performance, business strategy, plans and objectives of the Company for future operations (including growth potential). All forward-looking statements included in this Press release address matters that involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those indicated in such forward-looking statements and from past results, performance or achievements of the Company. Such forward-looking statements are based upon various assumptions and estimates regarding future events, including numerous assumptions regarding the Company’s present and future business strategies and future operating environment. Although the Company believes that these estimates and assumptions are reasonable, they may prove to be incorrect.

The information, opinions and forward-looking statements contained in this Press release speak only as at the date of this Press release and are subject to change without notice. The Company, its directors, agents, employees and advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this Press release to reflect any change in events, conditions or circumstances. To the extent permitted under the applicable provisions of law, neither the Company nor any of their affiliates, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss however arising from any use of this Press release or its contents or otherwise arising in connection with this Press release.

This Press release is not for distribution or use by any person or entity in any jurisdiction where such distribution or use would be contrary to local law or regulation or which would subject the Company or any of its affiliates to authorization, notification, licensing or other registration requirements under applicable laws. Any failure to comply with this restriction may constitute a violation of United States securities laws. Persons into whose possession this Press release comes should observe all such restrictions.

Obtain more information by contacting:
Małgorzata Siewierska
media@celonpharma.com